30 Day FDA and ICH Drug Development Regulations - Day 3 Pre-Clinical Development
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
30 Day FDA and ICH Drug Development Regulations - Day 3 Pre-Clinical Development
-
ナレーター：
-
著者：
このコンテンツについて
In this episode, we delve into the fascinating world of pre-clinical drug development—the critical stage where scientists determine whether a drug is safe and effective enough to move to human trials. Often overlooked, this phase lays the groundwork for every new medical breakthrough.
We explore:
- The rigorous pre-clinical studies, including safety pharmacology, toxicology, PK/PD (pharmacokinetics and pharmacodynamics), and genotoxicity testing.
- The role of the Investigational New Drug (IND) application, the gateway to human trials, and its key components like safety data, manufacturing processes, and clinical trial protocols.
- The ethical challenges of animal testing and the promising rise of alternatives like in vitro studies and computer modeling.
- Insights into how biostatistics shapes the understanding of pre-clinical data, ensuring the findings are reliable and meaningful.
Discover how the U.S. Code of Federal Regulations (CFR), Title 21, provides the framework for pre-clinical safety and why this phase is vital in bringing safe, effective drugs to market.
Takeaway Thought: Pre-clinical development may be behind the scenes, but it’s where the journey begins—filled with challenges, innovation, and the hope of life-changing discoveries.
Stay curious, keep learning, and join us as we uncover the meticulous effort behind every medical breakthrough!